Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma

Abstract

Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs survival in patients with metastatic melanoma, and sequential administration with lipilimumab may improve outcomes when switched at the appropriate time. Biomarkers are therefore needed to evaluate nivolumab efficacy soon after first administration. This study analyzed serum levels of soluble cluster of differentiation 163 (sCD163) in 59 cases of advanced cutaneous melanoma and 16 cases of advanced mucosal melanoma treated using nivolumab. Serum levels of sCD163 were significantly increased after 6 weeks in responders compared to non-responders after initial administration of nivolumab for cutaneous melanoma. In contrast, no significant difference between responders and non-responders was seen among patients with non-cutaneous melanoma. These results suggest that sCD163 may be useful as a biomarker for selecting patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

Malassezia‐derived aryl hydrocarbon receptor ligands enhance the CCL20/Th17/soluble CD163 pathogenic axis in extra‐mammary Paget's disease

“…sCD163 is a widely used marker of tumor development in skin cancer, as the main population of TAMs in skin cancer are CD163+ M2 macrophages . sCD163 is also a TAM marker that appears in the serum as a result of proteolytic shedding .…”

Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review

“…Only one patient is showing progressive disease. Fujimura et al 22 reported that the serum soluble CD163 level could be a predictor of the therapeutic efficacy of nivolumab in cases of malignant melanoma. Most tumor‐associated macrophages express CD163, and when activated, the cells release it as soluble CD163 (sCD163) into the blood.…”

Erfolgreiche Behandlung multipler Melanommetastasen mit einer Kombinationstherapie aus Nivolumab, Ipilimumab und Denosumab

“…Obwohl der Patient vor Behandlungsbeginn einen hohen CXCL5-Wert hatte, was für ein Ansprechen auf eine Monotherapie mit anti-PD1-Ak spricht [13], entschieden wir uns aufgrund anderer prognostischer Baseline-Faktoren (Metastasen in 4 Organen) für eine Kombinationstherapie aus Nivolumab plus Ipilimumab und Denosumab. Wie anhand unserer Biomarker-Systeme prognostiziert, lag nach 6 Wochen eine erhöhte Konzentration von löslichem (s)CD163 vor, die auf ein effektives Ansprechen auf die anti-PD1-Ak hindeutete [14]. Tatsächlich zeigte die Bildgebung mittels PET-CT 3 Monate nach der Behandlung ein partielles Ansprechen auf die Kombinationstherapie.…”